4 ms·

You don't need to have a deep understanding of biology to have a decent grasp of drug development. You're operating at a higher level of abstraction. You could

You don't need to have a deep understanding of biology to have a decent grasp of drug development. You're operating at a higher level of abstraction. You could argue such a CEO wouldn't be able to independently gauge the value of a new innovative medicine or approach, but that's where the CSO and others come into play.

ramraj07 6y ago
The issue is, what if the CSO is actually not competent? Can you tell if they're bullshitting or not? What if they are competent but giving incorrect advice because it's their pet project and invalidating it now means they look bad? How can you tell? In the end, I personally believe that the CEO needs to know enough of the underlying technology that their company is working on to smell bullshit. Otherwise his execs have a very high likelihood of taking them for granted. Ive seen it happen on a smaller scale repeatedly in my lab. If our professors are not well versed in one field of science, the postdocs and students will take advantage of it in every corner. This is especially true in biology. It doesn't matter how good your nanoparticle drug is, if you don't know that there are fundamental problems with immune recognition, half life, biodistrubution and non-specific binding, you would not know not to invest further. This evaluation is not something a CEO should outsource to another C level exec.